Docket No.: DU-P02-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mike West

Confirmation No.: 2470

Application No.: 10/692002

Art Unit: 1644

Filed: October 24, 2003

Examiner: Not Yet Assigned

For: BINARY PREDICTION TREE MODELING WITH MANY PREDICTORS AND ITS USES IN CLINICAL AND GENOMIC APPLICATIONS

January 25, 2005

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Pursuant to 37 CFR 1.98 (d)(1), copies of the references on the PTO/SB/08 are not required to be provided herewith since a copy of each reference was either submitted in an information disclosure statement or cited by the Office in connection with U.S. Serial No. 10/291,878 filed November 12, 2002, from which the subject application relies on for an earlier effective filing date under 35 U.S.C. 120. Reference CH1 was cited by the Examiner during prosecution of the parent application.

9619821.1

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. DU-P02-002. A duplicate copy of this paper is enclosed.

Dated: __January 25, 2005__   Respectfully submitted,

By: _____
Ignacio Perez de la Cruz
 Registration No.: 55,535
ROPES & GRAY LLP
45 Rockefeller Plaza
New York, New York 10111-0087
(212) 497-3613
(212) 497-3650 (Fax)
Attorneys/Agents For Applicant

2

9619821.1

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Complete if Known
Substitute for form 1449A/B/PTO	
	Application Number	10/692002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	October 24, 2003
	First Named Inventor	Mike West
	Art Unit	1644
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned
Sheet 1 of 2	Attorney Docket Number	DU-P02-002

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number — Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	SELLKE,T. et al., Calibration of pvalues for testing precise null hypotheses, *The American Statistician*, **55**, 62-71, (2001)	
	CB	BREIMAN, L., Statistical Modeling: The two cultures (with discussion), *Statistical Science*, **16** 199-225 (2001)	
	CC	OSBORNE, B.G., Applications of near infrared reflectance spectroscopy to compositional analysis of biscuits and biscuit doughs, *J. Sci. Food Agric.*, **35**, 99-105 (1984)	
	CD	BROWN, P.J., et al., The choice of variables in multivariate regression: A non-conjugate Bayesian decision theory approach, *Biometrika*, **86**, 635-648 (1999).	
	CE	LI, C. et al., Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. *Proc. Natl. Acad. Sci.*, **98**, 31-36 (2001)	
	CF	EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP, Polychemotherapy for early breast cancer: an overview of the randomized trials, , *Lancet*; 352:930-942 (2001)	
	CG	WEST, M., et al., Predicting the clinical status of human breast cancer by using gene expression profiles, Proc. Natl. Acad. Sci. USA 98, 11462-11467 (2001)	
	CH	SPANG, R., et al., Prediction and uncertainty in the analysis of gene expression profiles, In Silico Biol. 2, 0033 (2002)	
	CI	VAN T VEER, L.J., et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature 415, 530-536 (2002)	
	CJ	VAN DE VIJVER, M.J., et al., A gene-expression signature as a predictor of survival in breast cancer, N. Engl. J. Med. 347, 1999-2009 (2002)	
	CK	HUANG, E., et al., Gene expression predictors of breast cancer outcomes., Lancet in press (2003)	
	CL	POMEROY, S.L., et al., Prediction of central nervous system embryonal tumour outcome based on gene expression, Nature 415, 436-442 (2002)	
	CM	ALIZADEH, A.A., et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403, 503-511 (2000)	
	CN	ROSENWALD, A., et al., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.	

Examiner Signature		Date Considered	

9619810_1.DOC

Substitute for form 1449A/B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*	Application Number	10/692002
	Filing Date	October 24, 2003
	First Named Inventor	Mike West
	Art Unit	1644
	Examiner Name	Not Yet Assigned

Sheet		2	of	2	Attorney Docket Number	DU-P02-002

	CO	BHATTACHARJEE, A., et al., Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses, Proc. Natl. Acad. Sci. USA 98, 13790-13795 (2001)	
	CP	RAMASWARNY, S., et al., Multiclass cancer diagnosis using tumor gene expression signatures, Proc. Nat'l. Acad. Sci. 98, 15149-15154 (2001)	
	CQ	GOLUB, T.R., et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring, Science 286, 531-537 (1999)	
	CR	SHIPP, M.A., et al., Diffuse large B-cell lymphoma outcome prediction by gene expression profiling and supervised machine learning, Nat. Med. 8. 68-74 (2002)	
	CS	YEOH, E.-J., et al., Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling, Cancer Cell 1,133-143 (2002)	
	CT	CHENG, et al., Unique Features of Breast Cancer Res. Treat. 2000:63:213-23)	
	CU	MITTRA, I., et al., A Meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology, Eur.J.Cancer 1991;27:1574-83	
	CV	McGUIRE, W.L., Prognostic factors for recurrence and survival in human breast cancer, Breast Cancer Res Treat. 1987;10:5-9	
	CW	TANDON, A.K., et al., HER-2/neu oncogene protein and prognosis in breast cancer, JClin. Oncol. 1989;7:1120-8	
	CX	KASS, R.E., et al., Bayes' factors, J. Am. Stat. Assoc. 90, 773-795 (1998)	
	CY	HOETING, J., et al., Bayesian model averaging, A tutorial; Statistical Science, 14(4), 382-417 (1999)	
	CZ	CLYDE, M., Bayesian Statistics 6, Bernardo J.M. (ed.), pp. 157-185 (Oxford University Press, 1999)	
	CA1	JATOI, I., Significance of axillary lymph node metastasis in primary breast cancer, J. Clin. Oncol. 17, 2334-2340 (1999)	
	CB1	PHILOSOPHOV, L. et al., Medical Diagnostic Decision Rules Based on Mutually Dependent Diagnostic Factors, Comput. Biol. Med., Vol. 27, No. 4, 329-347, 1997.	
	CC1	LIAO, S. et al., Appropriate medical data categorization for data mining classification techniques, Med. Inform. Vol. 27, No. 1, 59-67 (2002).	
	CD1	CHAPMAN, W. et al., A Comparison of Classificaton Algorithms to Automatically Identify Chest X-Ray Reports That Support Pneumonia, Journal of Biomedical Informatics, 34, 4-14 (2001).	
	CE1	DAWSON, K., et al., A Bayesian approach to the identification of panmictic populations and the assignment of individuals", Genet. Res. Camb., 78, 59-77 (2001).	
	CF1	Copy of International Search Report dated July 1, 2004 from corresponding application no. PCT/US03/33946; citing references PHILOSOPHOV, LIAO, CHAPMAN and DAWSON.	
	CG1	SORLIE, T., et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, PNAS, Vol. 98, No. 19, 10869-10874 (2001)	
	CH1	D'HAESELEER at el. Bioinformatics, Volume 16, pages 707-726 (2000)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	

9619810_1.DOC

Application No. (if known): 10/692,002   Attorney Docket No.: DU-P02-002

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 553653039 US in an envelope addressed to:

> MS Amendment
> Commissioner for Patents
> P.O. Box 1450
> Alexandria, VA 22313-1450

on   January 25, 2005   ·
               Date

_____ Linda Blake _____
                       Signature

Linda Blake
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pages)

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/692002
Filing Date	October 24, 2003
First Named Inventor	Mike West
Art Unit	1644
Examiner Name	Not Yet Assigned

Total Number of Pages in This Submission	8	Attorney Docket Number	DU-P02-002

ENCLOSURES *(Check all that apply)*

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment/Reply
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [x] Information Disclosure Statement
- [ ] Certified Copy of Priority Document(s)
- [ ] Reply to Missing Parts/ Incomplete Application
  - [ ] Reply to Missing Parts under 37 CFR 1.52 or 1.53

- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Request for Refund
- [ ] CD, Number of CD(s) _____
  - [ ] Landscape Table on CD

Remarks

- [ ] After Allowance Communication to TC
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- [ ] Proprietary Information
- [ ] Status Letter
- [x] Other Enclosure(s) (please identify below):

SB/08
Return Receipt Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	ROPES & GRAY LLP
Signature	
Printed name	Ignacio Perez de la Cruz
Date	Jan 25, 2005	Reg. No.	55,535

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 553653039 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: __January 25, 2005__   Signature: _____ (Linda Blake)

9619822.1